Clinical Trial

A Phase Ib/II Study of SYS6090 Combination Therapy in Advanced Colorectal Cancer

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study constitutes an open-label, multi-cohort, multi-center Phase Ib/II clinical study, developed to assess the safety, tolerability, and therapeutic efficacy of SYS6090 injection when administered in combination with bevacizumab, or in triple combination with bevacizumab and chemotherapy, among patients diagnosed with advanced colorectal cancer.
Trial Details
NCT Number NCT07750041
Lead Sponsor CSPC Megalith Biopharmaceutical Co.,Ltd.
Conditions Unresectable Advanced or Metastatic Colorectal Cancer
Enrollment 260 participants
Start Date 2026-08-30
Primary Completion 2027-12-31 (estimated)
Study Completion 2029-08-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-06